This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fisher, M. Articles by Campbell, I. W Search for Related Content Social Bookmarking                         What's this?

Residual cardiovascular risk and practical management of type 2 diabetes

Glasgow Royal Infirmary, Glasgow, Scotland, miles.fisher{at}northglasgow.scot.nhs.uk

Ian W Campbell

Victoria Hospital, Kirkcaldy, Fife, Scotland

The evidence base for the optimal management of people with type 2 diabetes has increased dramatically over the last 10 years. Modern management of type 2 diabetes goes beyond glucose lowering and encompasses interventions to impact upon the cluster of cardiovascular risk factors associated with this complex condition. Large, randomised clinical trials have provided evidence for the use of antidiabetic agents, lipid-modulating therapies and antihypertensive agents in order to reduce cardiovascular morbidity and mortality in this high-risk group of patients. Such a multifactorial approach can become an issue for patients in terms of decreased compliance due to increased tablet burden and the complexity of drug regimen. Furthermore, despite optimal care in line with current best practice, people with type 2 diabetes still have a residual risk for cardiovascular disease compared with their counterparts without this condition. Pharmacological agents with additional benefits on cardiovascular risk factors may provide a future strategy for the optimal management of people with type 2 diabetes.

Key Words: case history • evidence-based medicine • risk factor management • multifactorial approach • residual cardiovascular risk.

References

• Almdal T., Scharling H., Jensen JS et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422-6.[Abstract/Free Full Text]
• Barnett AH, O'Gara G. Diabetes and the heart. Churchill Livingstone, London, 2003.
• Donnelly R. Managing cardiovascular risk in patients with diabetes. Br J Diabetes Vasc Dis 2005;5:325-9.[Abstract/Free Full Text]
• McCallum RW, Fisher M. From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes. Br J Diabetes Vasc Dis 2005;5:218-25.[Abstract/Free Full Text]
• European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. Diabet Med 1999;16:716-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Collins R., Armitage J., Parish S. et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• British Cardiac Society, British Hypertension Society, Diabetes UK et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl 5):v1-v52.[Free Full Text]
• UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.[Abstract/Free Full Text]
• National Institute for Health and Clinical Excellence. Management of Type 2 diabetes: Management of blood pressure and blood lipids (Guideline H). 2002.
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Parving HH, Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
• Dormandy JA, Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Charbonnel B., Dormandy J., Erdmann E. et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004;27:1647-53.[Abstract/Free Full Text]
• Erdmann E. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction. Accessible via http://www.proactive-results.com (Accessed 23 Nov. 2005).
• Dahlof B., Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-35.[Abstract/Free Full Text]
• Shepherd J., Barter P., Carmena R. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6.[Abstract/Free Full Text]
• Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.[Abstract/Free Full Text]
• Turner RC, Cull CA, Frighi V. et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Diabetes Care 1999;281:2005-12.
• Gæde P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348: 383-93.[Abstract/Free Full Text]
• Vermeire E., Wens J., Van Royen P. et al. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;CD003638.
• Krapek K., King K., Warren SS et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother 2004;38: 1357-62.[Abstract/Free Full Text]
• Keech A., Simes RJ, Barter P. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Colhoun HM After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? Lancet 2005;366:1829-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 2 suppl, S17-S23 (2006)
DOI: 10.1177/14746514060060020501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fisher, M. Articles by Campbell, I. W Search for Related Content Social Bookmarking                         What's this?